← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #548 OF 1,000 MOST-CITED

Label storage access limited to authorized personnel

FDA cited this observation 44 times across 44 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs44
BY FISCAL YEAR
FY20261
FY20255
FY20249
FY20232
FY20226
FY20211
FY20204
FY20197
FY20182
FY20173
FY20164

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.3× the rate of the average FDA-cited firm (25.0% vs 7.7%), across 44 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

Lantheus Medical Imaging, Inc. · North Billerica, Massachusetts · Drugs · 2026-04-09

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

K.W. Griffen Company · Norwalk, Connecticut · Drugs · 2025-05-16

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

Sun Pharmaceutical Industries, Inc. · Billerica, Massachusetts · Drugs · 2025-04-18

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

PureTek Corporation · San Fernando, California · Drugs · 2025-03-07

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

Holi Hemp LLC · Vancouver, Washington · Drugs · 2024-11-19

Access to the storage area for labels and labeling materials is not limited to authorized personnel.

Optimal Solution Labs LLC · Valencia, California · Drugs · 2024-11-06

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →